Leap Therapeutics Statistics
Share Statistics
Leap Therapeutics has 38.32M shares outstanding. The number of shares has increased by 49.67% in one year.
| Shares Outstanding | 38.32M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 28.57M |
| Failed to Deliver (FTD) Shares | 40.41K |
| FTD / Avg. Volume | 11.36% |
Short Selling Information
The latest short interest is 1.01M, so 2.63% of the outstanding shares have been sold short.
| Short Interest | 1.01M |
| Short % of Shares Out | 2.63% |
| Short % of Float | 3.53% |
| Short Ratio (days to cover) | 2.68 |
Valuation Ratios
The PE ratio is -1.04 and the forward PE ratio is -2.6.
| PE Ratio | -1.04 |
| Forward PE | -2.6 |
| PS Ratio | 0 |
| Forward PS | 3.3 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -1.93 |
| PEG Ratio | n/a |
Enterprise Valuation
Leap Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.64, with a Debt / Equity ratio of 0.
| Current Ratio | 5.64 |
| Quick Ratio | 5.64 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0.43 |
| Cash Flow / Debt | -167 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.35% and return on capital (ROIC) is -144.1%.
| Return on Equity (ROE) | -1.35% |
| Return on Assets (ROA) | -1.12% |
| Return on Capital (ROIC) | -144.1% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.51M |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -2.31% in the last 52 weeks. The beta is 0.22, so Leap Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.22 |
| 52-Week Price Change | -2.31% |
| 50-Day Moving Average | 3.01 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 47.92 |
| Average Volume (20 Days) | 355.71K |
Income Statement
In the last 12 months, Leap Therapeutics had revenue of $0 and earned -$81.41M in profits. Earnings per share was $-3.98.
| Revenue | 0 |
| Gross Profit | -427.00K |
| Operating Income | -87.04M |
| Net Income | -81.41M |
| EBITDA | -80.99M |
| EBIT | - |
| Earnings Per Share (EPS) | -3.98 |
Balance Sheet
The company has $70.64M in cash and $262.00K in debt, giving a net cash position of $70.38M.
| Cash & Cash Equivalents | 70.64M |
| Total Debt | 262.00K |
| Net Cash | 70.38M |
| Retained Earnings | -399.58M |
| Total Assets | 65.05M |
| Working Capital | 47.72M |
Cash Flow
In the last 12 months, operating cash flow was -$43.75M and capital expenditures $0, giving a free cash flow of -$43.75M.
| Operating Cash Flow | -43.75M |
| Capital Expenditures | 0 |
| Free Cash Flow | -43.75M |
| FCF Per Share | -2.14 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
LPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -134.46% |
| FCF Yield | -38.51% |
Analyst Forecast
The average price target for LPTX is $8, which is 170.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 170.3% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Jun 21, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 21, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -7.77 |
| Piotroski F-Score | 2 |